An interventional study of Platelet-Rich Plasma (PRP) Injections in Sexual Function, sponsored by Medstar Health Research Institute. Recruiting at 1 site in United States. Open to female participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-19.
Sponsored by Medstar Health Research Institute · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 128 studies in Sexual Dysfunction, Physiological with a site in United States — 17 open to participants now, 18 under way, none of them phase 3. Sexual Dysfunction, Physiological · United States.
Among the 128 studies in Sexual Dysfunction, Physiological with a site in United States, this one is the 57th largest by planned enrollment of the 108 interventional ones that give a count, is one of 5 that started in 2026, is one of 62 with no phase, reaches primary completion later than 9 of the 17 other live ones, and was the 128th registered.
386 studies on the registry are indexed under Sexual Dysfunction, Physiological; 73 are open to participants now.
Browse Sexual Dysfunction, Physiological studies →17 of the 128 studies in Sexual Dysfunction, Physiological with a site in United States are open now. Recruiting first, the newest first:
Icahn School of Medicine at Mount Sinai · Sites in United States
Ages 18+ · Women only
University Hospitals Cleveland Medical Center · Sites in United States
Ages 18–50 · Women only
Massachusetts General Hospital · Sites in United States
Ages 18+
University of Chicago · Sites in United States
Ages 18–45 · Women only
Stanford University · Sites in United States
Ages 18+ · Men only
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 47 Sexual Dysfunction, Physiological studies recruiting now, 24 (51%) set no upper age limit and 20 (43%) stop at 75 or younger; 2 take children under 18; 10 take healthy volunteers.
This study: 18 Years and older · female · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
128 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 3 · Phase 2 15 · Phase 3 16 · Phase 4 13
First in 1998; this study’s year is marked. 5 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 58 is below the median of 71 across 264 interventional studies indexed under Sexual Dysfunction, Physiological.
Median enrollment 60 across the 108 interventional studies, 98 across the 20 observational. Of the 93 that completed or were terminated, 37 (40%) have results posted.
This tab as a report to print or save as PDF → With an account.
27 of 128 have an industry lead sponsor. The 10 most frequent:
Medstar Health Research Institute is the lead sponsor of 162 studies on the registry; 32 are open to participants now.
Of its 14 completed or terminated interventional studies of FDA-regulated products, 7 (50%) have results posted.
Medstar Health Research Institute has 1 study filed under Sexual Dysfunction, Physiological — fewer than ten, so there is no comparison to draw.
5 of the studies in Sexual Dysfunction, Physiological with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04768777University of Alabama at BirminghamBehavioral Intervention for Physical Activity and Sexual Dysfunction in Multiple Sclerosis | 2026-12-01 |
| NCT05457972University Hospitals Cleveland Medical CenterPostpartum Vaginal Estrogen for Breastfeeding Patients | 2026-12-31 |
| NCT05468931Stanford UniversityProstate Stimulation for Sexual Dysfunction | 2027-06-01 |
| NCT06059586Indiana UniversityPre-Rehabilitation for Female Patients Undergoing Pelvic Radiotherapy | 2027-07 |
| NCT07948915Medstar Health Research InstituteSexual Function Outcomes Following Peri-clitoral PRP | 2027-11-01 |
Add all 5 to your calendar (.ics) → With an account.
Among the 128 studies in Sexual Dysfunction, Physiological with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The goal of this clinical trial is to learn if adding platelet-rich plasma (PRP) injections near the clitoris improves sexual function more than PRP injections in the vaginal wall alone. The study includes sexually active adults who were assigned female at birth. PRP is made from a person's own blood. It contains growth factors that may help tissue heal and renew.
The main questions it aims to answer are:
Does adding PRP near the clitoris improve sexual function 6 weeks after treatment, compared with vaginal wall PRP alone? Do any improvements last at 3 and 6 months? How painful are the injections, and what side effects do participants have?
Researchers will compare two groups. All participants will get PRP injected into the front wall of the vagina. One group will also get PRP injected near the clitoris. The other group will get a placebo (sham) injection near the clitoris: the needle goes under the skin, but nothing is injected. Participants will not know which group they are in.
Participants will:
Answer questionnaires about their health and sexual function before treatment. Come to one in-person visit, about 1 hour long. At this visit they will have blood drawn to make the PRP and receive the injections.
Rate their pain shortly after the injections. Complete 3 short online follow-up visits at 6 weeks, 3 months, and 6 months. At these visits they will answer questionnaires about sexual function and side effects.
**Background and Rationale**
Female sexual dysfunction (FSD) affects approximately 43% of women in the United States, and 23% report associated distress. Non-hormonal treatment options are limited. Platelet-rich plasma (PRP) is an autologous concentrate of platelets. On activation, platelets release growth factors, including vascular endothelial growth factor (VEGF) and platelet-derived growth factor (PDGF). These factors are hypothesized to promote angiogenesis, collagen synthesis, and neural regeneration in target tissues.
The Vaginal Injection of Platelet-Rich Plasma (VIP) trial was a single-blind randomized controlled trial conducted through the MedStar Health Research Institute. Compared with saline injection, anterior vaginal wall PRP produced greater improvement in Female Sexual Function Index (FSFI) total scores at 6 weeks and 6 months. PRP recipients also had higher global impression of improvement and no serious adverse events, although PRP injection was more painful than saline.
Commercial protocols (e.g., the "O-Shot") commonly add peri-clitoral injection to vaginal wall injection. Uncontrolled data that included peri-clitoral injection reported larger FSFI gains than those seen in the VIP trial (Runels et al., 2014; n=11). However, that study did not isolate the peri-clitoral component, and it reported two cases of extreme sexual arousal. Other peri-clitoral data come from studies without adjunctive vaginal wall injection.
The clitoral complex extends well beyond the glans to include the bulbs and crura. It is densely innervated and highly vascular, which makes it a plausible target for regenerative therapy. It is also a site where adverse sensory effects are of particular concern. No randomized data exist on the incremental benefit or risk of peri-clitoral PRP added to anterior vaginal wall PRP. This trial addresses that gap.
**Study Design**
This is a single-site, single-blind (participant-blinded), randomized, sham-controlled, parallel-group superiority trial. Both arms receive anterior vaginal wall PRP, so the design isolates the effect of the peri-clitoral component. Participants are randomized 1:1 using the REDCap randomization module. Unblinded study staff perform the randomization immediately before the procedure. Injecting physicians and study staff are unblinded. Allocation is concealed from participants until study completion, except in emergencies requiring knowledge of treatment assignment.
**Intervention Details**
Participants undergo venipuncture of 40-60 mL whole blood. Samples are labeled with study ID and date and transported within 30 minutes to an on-site centrifuge at MedStar Lafayette Centre. PRP is prepared with the Arthrex Angel system using a 15-minute centrifugation, which yields approximately 2-4 mL of leukocyte-rich PRP. PRP is used within 2 hours of centrifugation and requires no storage. This follows an established institutional orthopedic protocol. Residual blood product is discarded as biohazard waste, and no specimens are banked.
All injections are performed after topical anesthesia by trained, IRB-approved physicians using a 28-32 gauge needle with a superficial technique and retrograde withdrawal:
Participants are observed for 15 minutes after injection.
**Sample Size**
The sample size was calculated in PASS 2024 (v24.0.6) for a two-sided, two-sample t-test of the difference in baseline-to-6-week change in FSFI total score. Assumptions were α=0.05, 80% power, SD of 5.1 at each time point, and a within-subject correlation of 0.5. The target difference was 4.05 points, the distribution-based FSFI MCID. Published anchor-based estimates are similar. This requires 26 participants per arm. With 10% anticipated attrition, enrollment is 29 per arm (58 total).
**Statistical Analysis**
All tests are two-sided at α=0.05. Benjamini-Hochberg false discovery rate correction is applied to secondary analyses. Missing data are handled by complete-case analysis per outcome.
**Safety Monitoring**
Safety assessment focuses on outcomes specific to the peri-clitoral site: bleeding, infection, sensory changes (numbness, hypersensitivity), and unexpected or undesired arousal. An independent safety monitor reviews all adverse event data at 50% enrollment. Any serious adverse event is reported to the MHRI IRB, and enrollment is paused pending safety monitor review.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
All participants in this arm will receive active PRP injection into the anterior vaginal wall; they will receive a sham injection into the peri-clitoral sites.
Biological: Platelet-Rich Plasma (PRP) Injections
All participants in this arm will receive active PRP injection into the anterior vaginal wall; they will receive active PRP injection into the peri-clitoral sites.
Biological: Platelet-Rich Plasma (PRP) Injections
A single treatment session. 40-60 mL of autologous whole blood is processed with the Arthrex Angel system (15-minute centrifugation), yielding approximately 2-4 mL of leukocyte-rich platelet-rich plasma (PRP), which is used within 2 hours of preparation. After topical anesthesia, all participants receive two-thirds of the PRP volume injected superficially into the distal anterior vaginal wall, approximately 3 cm from the urethral meatus, using a 28-32 gauge needle. Experimental arm: The remaining PRP (approximately 1 mL) is delivered as two superficial injections of about 0.5 mL each near the junction of the clitoris, clitoral hood, and frenulum. Sham comparator arm: A needle is inserted at the same peri-clitoral sites without injecting any substance. Participants are blinded to peri-clitoral assignment.
Also known as: PRP
Change in Female Sexual Function Index Total Score
Change in total Female Sexual Function Index (FSFI) score from baseline to 6 weeks after treatment, compared between the peri-clitoral PRP and peri-clitoral sham arms. The FSFI is a validated 19-item self-report questionnaire assessing six domains of sexual function: desire, arousal, lubrication, orgasm, satisfaction, and pain. Total scores range from 2.0 to 36.0, and higher scores indicate better sexual function.
Time frame: Baseline and 6 weeks after treatment
Change in Female Sexual Function Index Total Score at 3 Months
Change in total Female Sexual Function Index (FSFI) score from baseline to 3 months after treatment, compared between arms. The FSFI is a validated 19-item self-report questionnaire. Total scores range from 2.0 to 36.0, and higher scores indicate better sexual function.
Time frame: Baseline and 3 months after treatment
Change in Female Sexual Function Index Total Score at 6 Months
Change in total FSFI score from baseline to 6 months after treatment, compared between arms. Total scores range from 2.0 to 36.0, and higher scores indicate better sexual function.
Time frame: Baseline and 6 months after treatment
Change in Female Sexual Function Index Domain Scores
Change from baseline in each of the six FSFI domain scores, compared between arms. The domains are desire (range 1.2-6.0), arousal (0-6.0), lubrication (0-6.0), orgasm (0-6.0), satisfaction (0.8-6.0), and pain (0-6.0). Higher scores indicate better function.
Time frame: Baseline, 6 weeks, 3 months, and 6 months after treatment
Proportion of Participants With Clinically Meaningful Improvement
Percentage of participants in each arm whose total FSFI score increases by at least 4.05 points from baseline, the minimal clinically important difference.
Time frame: Baseline, 6 weeks, 3 months, and 6 months after treatment
Proportion of Participants Above the Sexual Dysfunction Threshold
Percentage of participants in each arm with a total FSFI score of 26.55 or higher, the validated cutoff for distinguishing women with and without sexual dysfunction.
Time frame: 6 weeks, 3 months, and 6 months after treatment
Patient Global Impression of Improvement
Participant rating of change in sexual function since treatment on the Patient Global Impression of Improvement (PGI-I), a single-item 7-point scale from 1 (very much better) to 7 (very much worse). Lower scores indicate greater improvement. Compared between arms.
Time frame: 6 weeks, 3 months, and 6 months after treatment
Procedural Pain
Pain from the injection procedure, rated on a visual analog scale from 1 (least pain) to 10 (worst pain). Higher scores indicate more pain. Compared between arms.
Time frame: Approximately 10-15 minutes after injection on the day of treatment
Adverse Events
Number and type of adverse events in each arm. These include bleeding, infection, abnormal discharge, worsening or persistent pain, numbness, hypersensitivity, undesired changes in sexual arousal or genital sensation, and serious adverse events.
Time frame: From treatment through 6 months after treatment
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No — Individual participant data will not be shared. Data include sensitive sexual health and demographic information from a small, single-site sample, which poses a meaningful risk of re-identification, and participants were not consented for data sharing beyond the study team.
Start is estimated for Nov 2026; primary completion for Nov 2027, 12 months later.
Of 100 non-industry interventional studies with no phase under Sexual Dysfunction, Physiological, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 45. This study's planned 12 months is below that.
Counting every sponsor, half of 112 studies reached it within 20 months; a quarter within 10 and three quarters within 43.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Platelet rich plasma
Sexual Dysfunction, Physiological →
Medstar Health Research Institute →